Peptidomimetic Macrocycles Aqueous Formulation Stability
Solution Overview
Problem
There is a significant need for compounds that can bind to and modulate the activity of p53, MDM2, and MDMX proteins, as these proteins are often overexpressed in cancers and neutralize p53 activity, leading to malignant transformation.
Innovation Solution
Aqueous pharmaceutical formulations comprising p53-based peptidomimetic macrocycles that bind to MDM2 and/or MDMX proteins, inhibiting their interactions with p53, thereby stabilizing p53 activity and potentially treating cancer and hyperproliferative diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentration of peptidomimetic macrocycle is used (≥15 mg/mL), then therapeutic efficacy is improved, but solubility and formulation stability become problematic
Solution Approach 1:
The patent introduces micelle-forming agents (surfactants) as intermediary substances that enable the peptidomimetic macrocycle to form stable micellar structures at high concentrations. These surfactants act as mediators between the hydrophobic macrocycle and the aqueous formulation environment, allowing therapeutic concentrations to be achieved while maintaining formulation stability through controlled micelle formation.
Solution Approach 2:
The patent systematically optimizes multiple formulation parameters including surfactant concentration (0.1-5% w/v), pH (5.0-8.0), ionic strength, and temperature to control micelle formation and maintain stability. By changing these physical-chemical parameters, the formulation achieves both high macrocycle concentration and stable composition throughout storage and administration.
2Quantity of substance
If micelle-forming agents are used to enable high concentration formulation, then solubility is improved, but formulation complexity increases
Solution Approach 1:
The patent establishes specific parameter ranges for micelle-forming agents (0.1-5% w/v) and formulation conditions (pH 5.0-8.0, specific ionic strengths) that balance solubility enhancement with formulation simplicity. Within these optimized parameters, the formulation achieves high macrocycle concentration without requiring complex additional components or processing steps.
3Reliability
If peptidomimetic macrocycle concentration is increased, then p53 activity restoration is enhanced, but risk of precipitation increases
Solution Approach 1:
Micelle-forming agents serve as protective intermediaries that solubilize the hydrophobic peptidomimetic macrocycle at high concentrations, preventing precipitation. The surfactants form micellar structures that keep the macrocycle in solution while maintaining its biological activity for p53 restoration, thus eliminating the harmful precipitation effect.
Solution Approach 2:
The formulation system self-regulates precipitation risk through the micelle-forming agents that automatically form protective micellar structures when the macrocycle concentration increases. This self-organizing behavior prevents precipitation without requiring external intervention or complex stabilization mechanisms.
Data Source
AI summary
Aqueous pharmaceutical formulations, for parenteral administration, comprising peptidomimetic macrocycle or a pharmaceutically acceptable salt thereof wherein the peptidomimetic macrocycle binds to MDM2 and/or MDMX proteins are disclosed. Also disclosed are methods of treating diseases and disorders using the aqueous pharmaceutical formulations disclosed herein.